Jonathan Noble, Orlagh Bean, Ross Sayers, Ryan Cullen, Richard Beasley, Mark Weatherall
{"title":"使用哮喘控制问卷对FeNO的最小临床重要差异进行外部验证。","authors":"Jonathan Noble, Orlagh Bean, Ross Sayers, Ryan Cullen, Richard Beasley, Mark Weatherall","doi":"10.1111/cea.70131","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The minimal clinically important difference (MCID) for fractional exhaled nitric oxide (FeNO) in asthma is uncertain. The American Thoracic Society (ATS) suggests this may be a relative change ≥ 20%; however, this recommendation is not validated against a clinical outcome measure. A secondary analysis of two randomised controlled trials (RCTs) examining associations between changes in FeNO and the Asthma Control Questionnaire-5 (ACQ-5) may help estimate the MCID.</p><p><strong>Methods: </strong>The PRACTICAL and Novel START were 52-week RCTs that compared as-required short-acting beta-agonists with or without maintenance inhaled corticosteroids (ICS) versus as-required ICS-formoterol in mild-moderate asthma. In this secondary analysis, participants with measurements of FeNO and ACQ-5 were included. FeNO was analysed on the logarithm transformed scale. Logistic regression assessed associations between FeNO and ACQ-5 changes from baseline to end of study, relative to the ACQ-5 MCID (0.5 points). A t-test was used to compare the difference in log FeNO for those whose ACQ-5 fell by the MCID for an improvement in ACQ.</p><p><strong>Results: </strong>Data from 1553 participants were included. There was a weak association between the change in FeNO and change in ACQ-5; correlation coefficient was 0.08 (p = 0.002). The mean (SD) change in log FeNO for those with a clinically important improvement in ACQ-5 was -0.25 (0.64), N = 530; geometric mean ratio was 0.78, representing a 22% change in the geometric mean of FeNO. The change in log FeNO was -0.14 (0.60) for those without an improvement in ACQ-5, N = 852; geometric mean ratio was 0.87. The sensitivity and specificity for a 20% change in geometric mean FeNO were 47% and 57%, respectively.</p><p><strong>Conclusion: </strong>Changes in FeNO are a poor surrogate for changes in ACQ-5. The magnitude of FeNO changes in participants with an MCID improvement in ACQ-5 provides weak support for the ATS recommendation that the MCID for FeNO may be about a 20% relative change.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"External Validation of the Minimal Clinically Important Difference of FeNO Using the Asthma Control Questionnaire.\",\"authors\":\"Jonathan Noble, Orlagh Bean, Ross Sayers, Ryan Cullen, Richard Beasley, Mark Weatherall\",\"doi\":\"10.1111/cea.70131\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The minimal clinically important difference (MCID) for fractional exhaled nitric oxide (FeNO) in asthma is uncertain. The American Thoracic Society (ATS) suggests this may be a relative change ≥ 20%; however, this recommendation is not validated against a clinical outcome measure. A secondary analysis of two randomised controlled trials (RCTs) examining associations between changes in FeNO and the Asthma Control Questionnaire-5 (ACQ-5) may help estimate the MCID.</p><p><strong>Methods: </strong>The PRACTICAL and Novel START were 52-week RCTs that compared as-required short-acting beta-agonists with or without maintenance inhaled corticosteroids (ICS) versus as-required ICS-formoterol in mild-moderate asthma. In this secondary analysis, participants with measurements of FeNO and ACQ-5 were included. FeNO was analysed on the logarithm transformed scale. Logistic regression assessed associations between FeNO and ACQ-5 changes from baseline to end of study, relative to the ACQ-5 MCID (0.5 points). A t-test was used to compare the difference in log FeNO for those whose ACQ-5 fell by the MCID for an improvement in ACQ.</p><p><strong>Results: </strong>Data from 1553 participants were included. There was a weak association between the change in FeNO and change in ACQ-5; correlation coefficient was 0.08 (p = 0.002). The mean (SD) change in log FeNO for those with a clinically important improvement in ACQ-5 was -0.25 (0.64), N = 530; geometric mean ratio was 0.78, representing a 22% change in the geometric mean of FeNO. The change in log FeNO was -0.14 (0.60) for those without an improvement in ACQ-5, N = 852; geometric mean ratio was 0.87. The sensitivity and specificity for a 20% change in geometric mean FeNO were 47% and 57%, respectively.</p><p><strong>Conclusion: </strong>Changes in FeNO are a poor surrogate for changes in ACQ-5. The magnitude of FeNO changes in participants with an MCID improvement in ACQ-5 provides weak support for the ATS recommendation that the MCID for FeNO may be about a 20% relative change.</p>\",\"PeriodicalId\":10207,\"journal\":{\"name\":\"Clinical and Experimental Allergy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Allergy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/cea.70131\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Allergy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/cea.70131","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
External Validation of the Minimal Clinically Important Difference of FeNO Using the Asthma Control Questionnaire.
Background: The minimal clinically important difference (MCID) for fractional exhaled nitric oxide (FeNO) in asthma is uncertain. The American Thoracic Society (ATS) suggests this may be a relative change ≥ 20%; however, this recommendation is not validated against a clinical outcome measure. A secondary analysis of two randomised controlled trials (RCTs) examining associations between changes in FeNO and the Asthma Control Questionnaire-5 (ACQ-5) may help estimate the MCID.
Methods: The PRACTICAL and Novel START were 52-week RCTs that compared as-required short-acting beta-agonists with or without maintenance inhaled corticosteroids (ICS) versus as-required ICS-formoterol in mild-moderate asthma. In this secondary analysis, participants with measurements of FeNO and ACQ-5 were included. FeNO was analysed on the logarithm transformed scale. Logistic regression assessed associations between FeNO and ACQ-5 changes from baseline to end of study, relative to the ACQ-5 MCID (0.5 points). A t-test was used to compare the difference in log FeNO for those whose ACQ-5 fell by the MCID for an improvement in ACQ.
Results: Data from 1553 participants were included. There was a weak association between the change in FeNO and change in ACQ-5; correlation coefficient was 0.08 (p = 0.002). The mean (SD) change in log FeNO for those with a clinically important improvement in ACQ-5 was -0.25 (0.64), N = 530; geometric mean ratio was 0.78, representing a 22% change in the geometric mean of FeNO. The change in log FeNO was -0.14 (0.60) for those without an improvement in ACQ-5, N = 852; geometric mean ratio was 0.87. The sensitivity and specificity for a 20% change in geometric mean FeNO were 47% and 57%, respectively.
Conclusion: Changes in FeNO are a poor surrogate for changes in ACQ-5. The magnitude of FeNO changes in participants with an MCID improvement in ACQ-5 provides weak support for the ATS recommendation that the MCID for FeNO may be about a 20% relative change.
期刊介绍：
Clinical & Experimental Allergy strikes an excellent balance between clinical and scientific articles and carries regular reviews and editorials written by leading authorities in their field.
In response to the increasing number of quality submissions, since 1996 the journals size has increased by over 30%. Clinical & Experimental Allergy is essential reading for allergy practitioners and research scientists with an interest in allergic diseases and mechanisms. Truly international in appeal, Clinical & Experimental Allergy publishes clinical and experimental observations in disease in all fields of medicine in which allergic hypersensitivity plays a part.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
